Equasens Posts Strong Growth Amid Leadership and AI Transformation

VILLERS-LÈS-NANCY, France – March 30, 2026 – Digital healthcare leader Equasens has announced a robust financial performance for fiscal year 2025, signaling sustained momentum through strategic acquisitions, deep investment in artificial intelligence, and strong alignment with European healthcare initiatives. The company reported a 9.1% increase in revenue to €236.5 million, with net profit climbing 8.8% to €41.1 million, even as it prepares for a significant leadership transition and navigates a complex tax dispute.

The results paint a picture of a mature company executing a multi-pronged growth strategy in a rapidly expanding market. While navigating the operational challenges of supply chain constraints and regulatory scrutiny, Equasens is doubling down on its core mission to integrate technology more deeply into the European healthcare ecosystem.

A Picture of Financial Health

Equasens' 2025 financial results underscore a year of consistent growth across all key indicators. Revenue and EBITDA both grew by an identical 9.1%, reaching €236.5 million and €66.7 million respectively, a parallel movement that highlights effective cost management alongside expansion. This performance is anchored by a strong base of recurring revenue, with Annual Recurring Revenue (ARR) climbing 8.8% to €108.0 million, demonstrating the stability of its software-as-a-service (SaaS) and subscription-based models.

While impressive, the company's 9.1% growth rate is set against the backdrop of a European digital health market experiencing explosive expansion, with some market segments projected to grow at a compound annual rate of over 17%. However, where a few years ago the market favored rapid, cash-burning growth, analysts note a 2025 trend towards rewarding profitability and proven, scalable business models. In this context, Equasens’ steady, profitable growth and strong cash generation of €56.7 million position it as a stable pillar in the sector, contrasting with competitors like Oracle Health (formerly Cerner), which has faced integration challenges, and others like Dedalus, which are focused on deleveraging.

Frédérique Schmidt, Chief Financial Officer, highlighted this stability, stating, “This year’s performance confirms the strength of Equasens’ business model, supported by recurring revenue... and strong cash generation.” This financial foundation, she added, provides the “agility and financial flexibility to support our technological developments, particularly in artificial intelligence, as well as our M&A strategy.”

Performance was strong across most divisions. The AXIGATE LINK division, serving nursing homes and hospitals, grew revenue by a stellar 17%, while the E-CONNECT and MEDICAL SOLUTIONS divisions posted even higher growth rates of 31.4% and 26.1% respectively, showcasing the success of new product launches and strategic acquisitions.

Strategy in Action: AI, Acquisitions, and Policy

The engine behind Equasens' financial success is a clear strategic focus on technological innovation and market consolidation. The company is aggressively pushing into artificial intelligence, not as a theoretical concept, but as a practical tool to enhance its core software offerings. CEO Denis Supplisson commented on the strategy, noting the goal is to “begin integrating agentic AI layers, delivering greater value to clients through enhanced decision support.” This involves developing capabilities to automate tasks and analyze vast datasets in real-time, all hosted on the company's proprietary and sovereign healthcare cloud—a key differentiator in a market rightly concerned with data security and sovereignty.

This technological push is complemented by a shrewd acquisition strategy. The January 2026 acquisition of an 80% stake in Erevo, a leading digital training platform for healthcare professionals, is a prime example. This move not only expands Equasens' portfolio into the e-learning market but also creates powerful synergies. By integrating Erevo's training modules with its software solutions, Equasens can improve user adoption and offer a more holistic service package, deepening its relationship with healthcare providers.

These strategies are perfectly timed to capitalize on major government initiatives. The French "Ségur du numérique en santé" (Digital Ségur for Health) program is injecting billions into modernizing the country's healthcare infrastructure. Equasens has proactively aligned its solutions with the program's requirements for interoperability and security. With all of its Medical Solutions software enrolled under Wave 2 of the Ségur plan, the company is exceptionally well-positioned to benefit from public funding and the government-mandated push for digitalization, with deployments scheduled for late 2026 and early 2027.

An End of an Era, A New Chapter Begins

Amidst this period of growth and strategic execution, Equasens is undergoing its most significant leadership change in its 35-year history. Thierry Chapusot, the Group's founder and Chairman of the Board, has announced he will not seek renewal of his term. His departure marks the end of a remarkable entrepreneurial era, with the Board paying tribute to his “entrepreneurial vision and his decisive role in the creation and development of the Group.”

Passing the torch is François-Pierre Marquier, who was appointed Deputy CEO effective April 1. Marquier is an established figure within the company, having joined in 2021 and quickly rising to lead the core Pharmagest division. His extensive background in senior sales and marketing roles at software giant Cegid Group suggests his appointment is a strategic move to professionalize and scale the company's commercial operations. This transition signals a shift from a founder-led company to a new phase of structured corporate growth, with a leader well-versed in executing strategy in a large, publicly-traded software environment.

Navigating Headwinds and Future Horizons

Despite the positive outlook, Equasens is not without its challenges. The company disclosed it is contesting a €2.6 million tax reassessment from French authorities for fiscal year 2021. The dispute centers on the application of the IP Box regime, a tax incentive designed to encourage domestic research and development. Such challenges from tax authorities often hinge on complex interpretations of whether R&D expenditures are directly linked to income-generating intellectual property. While the company is pursuing legal action, the reassessment represents a potential financial and reputational risk.

On the operational front, the E-CONNECT division is bracing for supply constraints in the global RAM market, which could affect both the price and availability of components for its hardware terminals in 2026. The company has stated it is implementing measures like forward purchasing and supplier diversification to mitigate the impact.

Nevertheless, the company's forward-looking statements express confidence. With a strengthened net cash position of €83.6 million and a clear roadmap for 2026, Equasens intends to build on its leadership position. The focus remains squarely on leveraging its technological prowess in AI and its secure cloud infrastructure to drive further integration and efficiency across the European healthcare landscape, turning the promise of digital health into a daily, operational reality.